S&P 500, Microsoft Corporation, Alphabet Inc Class A, PACCAR Inc. Read 's Market Analysis on Investing.com India ...

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and ...

Nassif, who will also join Neogen’s Board of Directors, succeeds John Adent who is stepping down after eight years with the company. Nassif currently serves as Global President of the Point-of-Care ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company's leadership in multimodal biomarkers and early detection New ...

Los Angeles Capital Management LLC dramatically increased its Johnson & Johnson holdings by 213.6% in Q1, now owning ...

The Diffuse Large B-cell Lymphoma (DLBCL) market is witnessing significant growth, driven by advancements in targeted immunotherapies like CAR-T cell therapy and bispecific antibodies. These therapies ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Landmark approval is based on results from the Phase 3 AQUILA study, showing fixed-duration treatment with daratumumab significantly reduced the risk of ...

Founded in 1998, Genmab develops customised antibodies for use in cancer treatments. Historically, the group has licensed its technology and the commercialisation of its drugs to large pharma giants ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has received approval from the European Commission (EC) ...

In this video, Sham Mailankody, MBBS, discusses results from a first-in-human study of JNJ-5322, a next-generation trispecific antibody for treatment of patients with relapsed or refractory multiple ...